Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:50:19.618Z.
Calculation as of: 2026-10-06T12:50:19.618Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1aa4897ea94b4447735fa2b7e4a8bb5a18d1bcefabda34b81af7232f4abbcb6a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$6.76M
Price/OCF Ratio
N/A
TTM Avg
2077.04
3Y Avg
2435.48
5Y Avg
5326.60
Market Cap
$7.03M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.44M
Price/OCF Ratio
N/A
TTM Avg
1251.33
3Y Avg
3596.77
5Y Avg
3596.77
Market Cap
$7.31M
Price/OCF Ratio
N/A
TTM Avg
41006.18
3Y Avg
41006.18
5Y Avg
41006.18
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclarion, Inc. (ACON) | $6.74M | N/A | N/A | N/A | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | N/A | 2077.04 | 2435.48 | 5326.60 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | N/A | 5.48 | 12.65 | 12.65 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | N/A | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | N/A | 1251.33 | 3596.77 | 3596.77 |
| Biomerica, Inc. (BMRA)vs › | $6.34M | N/A | 119.62 | 119.62 | 119.62 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | N/A | 41006.18 | 41006.18 | 41006.18 |
| Femasys Inc. (FEMY)vs › | $6.10M | N/A | N/A | N/A | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
